Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE

Amgen and Novartis First to Launch Humira Biosimilars

By Catherine Sbeglia | October 16, 2018

Amgen and Novartis have outrun Samsung and Mylan in the race to get their approved biosimilar versions of AbbVie’s Humira (adalimumab) to market. 

Amgen will launch Amgevita in markets across Europe beginning on Oct. 16, 2018. Amgevita is the first adalimumab biosimilar to be approved by the European Commission (EC). At the same time, Novartis’ Sandoz unit announced that it will launch its Humira biosimilar Hyrimoz initially in the UK, with other markets set to follow. 

In 2017, Amgevita became the first Humira biosimilar approved in Europe, with the product authorized in all indications, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, plaque psoriasis, Crohn’s disease, and ulcerative colitis. Amgevita will be available in a prefilled syringe and pre-filled pen.

Regulators in Europe also have approved Samsung Bioepis’ Imraldi, and Mylan and Fujifilm Kyowa Kirin Biologics’ Hulio, both biosimilar versions of Humira set to launch in the Europe. However, Boehringer Ingelheim’s version, called Cyltezo, will not be launched in Europe due to ongoing patent litigation with AbbVie in the U.S.

Just last week, AbbVie and Sandoz reached a global resolution of all intellectual property-related litigation over Hyrimoz, in which AbbVie granted Sandoz a non-exclusive license to intellectual property relating to Humira.

(Sources: Amgen; Novartis)

Related Articles Read More >

Genentech roche
Roche, Genentech to build $700M drug manufacturing plant in North Carolina
These are the logos of Otsuka Medical and ICU Medical.
ICU Medical, Otsuka Pharmaceutical Factory launch joint IV supply chain venture
Amgen
Amgen to spend $900M to expand U.S. biopharma manufacturing
Roche
Roche to invest $50B in U.S. over next five years
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE